)
Visual
test
Biora Therapeutics
Biora Therapeutics (BIOR) investor relations material
Biora Therapeutics has been otc
Biora Therapeutics Q3 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2024 earnings summary14 Nov, 2024
Executive summary
Clinical-stage biotech focused on oral biotherapeutics, with NaviCap for GI-targeted and BioJet for systemic delivery; advanced development of smaller, higher-capacity BioJet device with animal testing planned in Q4 2024.
Shifted partnering strategy to focus on licensing BioJet device, citing strong pharma interest.
No significant product revenue; pipeline in early clinical and preclinical stages, with ongoing R&D investment.
Underwent two reverse stock splits (1-for-25 in Jan 2023, 1-for-10 in Oct 2024) to maintain Nasdaq compliance.
Substantial doubt exists about ability to continue as a going concern due to limited cash and high accumulated deficit.
Financial highlights
Revenue for Q3 2024 was $32,000, up from $4,000 in Q3 2023; nine-month revenue was $892,000.
Net loss for Q3 2024 was $18.4M, improved from $73.5M in Q3 2023; nine-month net loss was $16.1M, improved from $108.7M.
Operating expenses for Q3 2024 were $16.3M, down from $23.3M in Q3 2023 and $16.1M in Q2 2024.
Cash and equivalents at September 30, 2024 were $3.0M–$3.2M, with a working capital deficit and $967.1M accumulated deficit.
Cash used in operations for the nine months ended September 30, 2024 was $32.2M.
Outlook and guidance
Current cash is not expected to fund operations for 12 months; additional capital is required.
Plans to raise capital through equity offerings, debt financings, or strategic transactions.
R&D expenses expected to remain flat in 2024 as clinical trials continue.
Plans to share additional canine study data and begin primate studies with BioJet device in Q4 2024.
Operating cash burn reduced by 40% to under $2.5M per month going forward.
BioJet licensing strategy and Q1 capacity
Nasdaq compliance plan and noteholder risk
BT-600 larger trial regulatory path
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 5 FebBMY
Growth Portfolio expansion and pipeline catalysts drive strong 2026 outlook despite legacy headwinds. - 5 FebPAHC
Net sales rose 21% and net income surged, prompting a raised outlook and strong margin gains. - 5 FebUGI
Q1 EBIT rose 5% to $441M, with strong gas demand and $215M in divestitures planned. - 5 FebBSANTANDER
Net income up 23% YoY, ROE/ROAE 23.5%, efficiency 36%, with strong digital and fee growth. - 5 FebCI
2025 revenue up 11% to $275B; 2026 EPS guidance at $30.25+ with ongoing PBM model changes. - 5 FebICE
Record revenue, double-digit EPS growth, and strong 2026 outlook across all segments. - 5 FebSTE
Q3 revenue up 9% and adjusted EPS at $2.53; 2026 outlook held despite $55M tariff impact. - 5 FebKGS
$675M acquisition expands distributed power reach, targeting data center growth and accretive returns. - 5 FebGENI
A $1.2B deal creates a digital sports media powerhouse, boosting scale and profitability. - 5 FebMCFT
Q2 FY2026 sales up 13.2%, guidance raised, and $232M Marine Products deal to drive synergies.
Biora Therapeutics
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Biora Therapeutics Inc. is a biotechnology company focused on developing innovative oral biotherapeutics for the treatment of chronic diseases. The company specializes in creating drug delivery systems that allow for the targeted delivery of therapeutics to the gastrointestinal (GI) tract, aiming to improve treatment outcomes and patient experiences. Biora’s pipeline includes therapies for conditions such as inflammatory bowel disease (IBD) and other GI-related disorders, leveraging its proprietary technology platforms for precision medicine. The company is headquartered in San Diego, California, USA, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage